You are here

COPD Drug Symbicort (Budesonide/ Formoterol) More Effective Than Advair (Fluticasone/Salmeterol) in ‘Real World’ Study

Disease flares and hospitalizations reduced (Mar. 19)

An analysis of data from the “real world” PATHOS trial, published in the Journal of Internal Medicine, has shown that patients with chronic obstructive pulmonary disease (COPD) treated with Symbicort Turbuhaler (budesonide/formoterol, AstraZeneca) are significantly less likely to experience COPD-related flares and are significantly less likely to be hospitalized for COPD compared with patients treated with Advair (fluticasone/salmeterol, GlaxoSmithKline).

Overall, budesonide/formoterol reduced the annual rate of moderate-to-severe exacerbations by 26% compared with fluticasone/salmeterol (0.80 vs. 1.09 patient-years, respectively; P P P

The 11-year PATHOS study, conducted in Sweden, retrospectively examined the medical records of 5,468 patients treated with inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination therapy from 1999 to 2009, for a total of 19,000 patient-years. A cohort of patients treated with budesonide/formoterol were individually matched with an equal number of patients treated with another ICS/LABA regimen, fluticasone/salmeterol. Exacerbations were defined as medical interventions, such as hospitalizations, emergency room visits, and prescriptions of oral steroids or antibiotics due to COPD deterioration.

Source: AstraZeneca; March 19, 2013.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs